Cancer Panels use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS facilitates sequencing of large genomic regions, high numbers of genes, and/or high numbers of samples in a single, efficient and cost-effective assay.
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
DATE: April 26, 2017TIME: 9:00AM PT, 12:00PM ETBiopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with li...
DATE: April 20th, 2017TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZSTWith increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that t...
Psychiatric disorders are among the leading causes of disability worldwide. One fifth of the population will suffer from a psychiatric disorder in their lifetime. Antipsychotic and antidepres...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
The aim of the learning healthcare system is to leverage data stored in the electronic health record (EHR) to gain insights into and improve healthcare delivery. Laboratory testing represents...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
Medicare is clearly moving to a pay for value paradigm, and commercial payers continue their own march away from traditional fee-for-service payment. How can you develop and articulate a pers...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
In order to realize the benefits of personalized cancer therapy, increasing demands are placed upon clinical laboratories to provide timely, comprehensive, clinically actionable, and analytic...
Self-assembling protein microarrays arrays can be used to study protein-protein interactions, protein-drug interactions, search for enzyme substrates, and as tools to search for disease bioma...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
Medical genetics is a specialty of medicine that encompasses patients at all ages (prenatal, pediatric, adult), as well as all organ systems. As the genetic causes of more diseases have been ...
While next-generation sequencing has proven to be a very useful tool in basic research, two major hurdles remain for its broad adoption in the clinical research setting: lack of seamless work...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
Human microbiome projects have delivered our first glimpse into the microbial communities that reside in and on our bodies. Building on these efforts the research community has begun to corre...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq).Many analyses, such as...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
DATE: April 26, 2017TIME: 9:00AM PT, 12:00PM ETBiopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with li...
DATE: April 20th, 2017TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZSTWith increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that t...
Psychiatric disorders are among the leading causes of disability worldwide. One fifth of the population will suffer from a psychiatric disorder in their lifetime. Antipsychotic and antidepres...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
The aim of the learning healthcare system is to leverage data stored in the electronic health record (EHR) to gain insights into and improve healthcare delivery. Laboratory testing represents...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
Medicare is clearly moving to a pay for value paradigm, and commercial payers continue their own march away from traditional fee-for-service payment. How can you develop and articulate a pers...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
In order to realize the benefits of personalized cancer therapy, increasing demands are placed upon clinical laboratories to provide timely, comprehensive, clinically actionable, and analytic...
Self-assembling protein microarrays arrays can be used to study protein-protein interactions, protein-drug interactions, search for enzyme substrates, and as tools to search for disease bioma...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
Medical genetics is a specialty of medicine that encompasses patients at all ages (prenatal, pediatric, adult), as well as all organ systems. As the genetic causes of more diseases have been ...
While next-generation sequencing has proven to be a very useful tool in basic research, two major hurdles remain for its broad adoption in the clinical research setting: lack of seamless work...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
Human microbiome projects have delivered our first glimpse into the microbial communities that reside in and on our bodies. Building on these efforts the research community has begun to corre...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq).Many analyses, such as...
Follow
